Clinical Trial Update: Apatinib as Second Line Therapy in Patients With Advanced Refractory Biliary Tract Cancers [Phase 2]

View source ↗

Summary

This document provides a Phase 2 trial update on apatinib as second-line therapy for advanced refractory biliary tract cancers.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer

Drugs mentioned

• Apatinib (apatinib)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Biliary Tract Cancer | Phase 2 | Status: UNKNOWN